This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health (CAH) Surpasses Earnings Estimates in Q1
by Nabaparna Bhattacharya
Cardinal Health (CAH) Q1 results benefit from strong sales in the Pharmaceutical and the Medical segments.
Cardinal Health (CAH) Beats on Earnings & Revenues in Q1
by Zacks Equity Research
Cardinal Health's (CAH) solid segmental performance buoys optimism. FY19 view reiterated.
Earnings Preview: Cardinal Health (CAH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Cardinal Health's (CAH) Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q1; medical-gloves sub-segment likely to be soft.
New Strong Sell Stocks for October 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Is Cardinal (CAH) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health Product Spectrum Broad, Competition Rife
by Zacks Equity Research
Cardinal Health's (CAH) strategic buyouts lend it a competitive edge; the Cordis unit lacks luster.
Cardinal Health (CAH) Surpasses Earnings Estimates in Q4
by Zacks Equity Research
Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.
Cardinal Health (CAH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 8.60% and 2.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Earnings on Aug 6: CAH, HSIC & More
by Zacks Equity Research
The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.
3 Dental Stocks to Top Earnings Estimates This Season
by Zacks Equity Research
On upbeat consumer sentiment and increased business investments, the dental supplies industry appears to be in the pink of health now.
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
Options Traders Expect Huge Moves in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) needs investors to pay close attention to the stock based on moves in the options market lately.
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) is likely to witness solid growth in the core Pharmaceutical segment in Q4 results. However, lackluster performance in the Cordis unit is likely to mar prospects.
Here's Why You Should Hold Onto Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health's (CAH) unique portfolio of Medical and Pharmaceutical offerings will lend it a competitive edge in the MedTech space. However, the company faces sluggishness in the exam-gloves unit.
Is Cardinal Health (CAH) a Great Stock for Value Investors?
by Zacks Equity Research
Cardinal Health (CAH) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
Why Is Cardinal Health (CAH) Up 2.5% Since Its Last Earnings Report?
by Zacks Equity Research
Cardinal Health (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Cardinal Health (CAH) Could Be Positioned for a Slump
by Zacks Equity Research
Cardinal Health (CAH) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Cardinal Health (CAH) Misses on Earnings in Q3, Beats Revenue
by Zacks Equity Research
Cardinal Health's (CAH) adjusted earnings decreased 9.2% on a year-over-year basis to $1.39 per share.
Is Cardinal Health (CAH) a Great Stock for Value Investors Right Now?
by Zacks Equity Research
Let's put Cardinal Health (CAH) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Cardinal Health (CAH) Up 7.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Cardinal Health (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Lockheed Martin, Raytheon and Cardinal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Lockheed Martin, Raytheon and Cardinal Health
M&A Continues to Fuel Market
by Fred Lovely
One of the best kept secrets of this US stock market is the shrinking share count available to investors to purchase.
Cardinal (CAH) Beats on Q2 Earnings and Revenues
by Sreyoshi Mukherjee
Cardinal Health (CAH) gains on strong segmental performances in fiscal Q3 18.